<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04290676</url>
  </required_header>
  <id_info>
    <org_study_id>DEXYCU Retrospective Study 001</org_study_id>
    <nct_id>NCT04290676</nct_id>
  </id_info>
  <brief_title>DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001</brief_title>
  <acronym>DEXYCURetro</acronym>
  <official_title>DEXYCU (Dexamethasone Intraocular Suspension) 9% Retrospective Study 001</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EyePoint</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EyePoint</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retrospective study to provide clinical outcomes with DEXYCU (dexamethasone intraocular
      suspension) 9%.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This retrospective study is intended to provide large-scale, real-world data on clinical
      outcomes with DEXYCU (dexamethasone intraocular suspension) 9%.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 13, 2019</start_date>
  <completion_date type="Actual">May 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Operative Outcome (anti-inflammatory efficacy - Intraocular Pressure)</measure>
    <time_frame>Post-Operative at Day 1</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Outcome tolerability - Product Tolerated [surgical complications questionnaire (e.g., Bleed, Use of Iris Hook, Other, None)]</measure>
    <time_frame>Post-Operative at Day 1</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Outcome intraocular behavior of the product - Rank Efficacy vs. Topical Steroid Grading Scale (e.g., Superior, Comparable, Not Recorded)</measure>
    <time_frame>Post-Operative at Day 1</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Outcome (anti-inflammatory efficacy - Intraocular Pressure)</measure>
    <time_frame>Post-Operative at Day 8</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Outcome Product Tolerated [surgical complications questionnaire (e.g., Bleed, Use of Iris Hook, Other, None)]</measure>
    <time_frame>Post-Operative at Day 8</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Outcome intraocular behavior of the product - Rank Efficacy vs. Topical Steroid Grading Scale (e.g., Superior, Comparable, Not Recorded)</measure>
    <time_frame>Post-Operative at Day 8</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Outcome (anti-inflammatory efficacy - Intraocular Pressure)</measure>
    <time_frame>Post-Operative at Day 14</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Outcome Product Tolerated [surgical complications questionnaire (e.g., Bleed, Use of Iris Hook, Other, None)]</measure>
    <time_frame>Post-Operative at Day 14</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Outcome intraocular behavior of the product - Rank Efficacy vs. Topical Steroid Grading Scale (e.g., Superior, Comparable, Not Recorded)</measure>
    <time_frame>Post-Operative at Day 14</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Outcome (anti-inflammatory efficacy - Intraocular Pressure)</measure>
    <time_frame>Post-Operative at Day 30</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Outcome Product Tolerated [surgical complications questionnaire (e.g., Bleed, Use of Iris Hook, Other, None)]</measure>
    <time_frame>Post-Operative at Day 30</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Outcome intraocular behavior of the product - Rank Efficacy vs. Topical Steroid Grading Scale (e.g., Superior, Comparable, Not Recorded)</measure>
    <time_frame>Post-Operative at Day 30</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Outcome (anti-inflammatory efficacy - Intraocular Pressure)</measure>
    <time_frame>Post-Operative Day: Unscheduled up to Day 30</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Outcome Product Tolerated [surgical complications questionnaire (e.g., Bleed, Use of Iris Hook, Other, None)]</measure>
    <time_frame>Post-Operative Day: Unscheduled up to Day 30</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Outcome intraocular behavior of the product - Rank Efficacy vs. Topical Steroid Grading Scale (e.g., Superior, Comparable, Not Recorded)DEXYCU vs. Topical Steroid)</measure>
    <time_frame>Post-Operative Day: Unscheduled up to Day 30</time_frame>
    <description>Post-Operative Cataract Assessments after the use of DEXYCU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Satisfaction Questionnaire with DEXYCU (Based on feedback to the Surgeon)</measure>
    <time_frame>Post-Operative up to Day 30</time_frame>
    <description>Patient satisfaction after the use of DEXYCU.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Surgeon Satisfaction Questionnaire with DEXYCU (Questions include: Ease of use, Postoperative regimen, DEXYCU time efficiency for physicians and staff)</measure>
    <time_frame>Post-Operative up to Day 30</time_frame>
    <description>Surgeon satisfaction after the use of DEXYCU.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Unanticipated reportable adverse events</measure>
    <time_frame>Post-Operative at Day 1</time_frame>
    <description>Unanticipated events related to DEXYCU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unanticipated reportable adverse events</measure>
    <time_frame>Post-Operative at Day 8</time_frame>
    <description>Unanticipated events related to DEXYCU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unanticipated reportable adverse events</measure>
    <time_frame>Post-Operative at Day 14</time_frame>
    <description>Unanticipated events related to DEXYCU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unanticipated reportable adverse events</measure>
    <time_frame>Post-Operative at Day 30</time_frame>
    <description>Unanticipated events related to DEXYCU.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unanticipated reportable adverse events</measure>
    <time_frame>Post-Operative Day: Unscheduled up to Day 30</time_frame>
    <description>Unanticipated events related to DEXYCU.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">527</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>DEXYCU (dexamethasone intraocular suspension) 9%.</arm_group_label>
    <description>DEXYCU (dexamethasone intraocular suspension) 9%. Single dose, intraocularly in the posterior chamber at the end of surgery. The dose is 0.005 mL of dexamethasone 9% (equivalent to 517 micrograms).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DEXYCU (dexamethasone intraocular suspension) 9%.</intervention_name>
    <description>DEXYCU contains dexamethasone 9% w/w (103.4 mg/mL) as a sterile suspension for intraocular ophthalmic administration. DEXYCU is provided as a kit for administration of a single dose of 0.005 mL of 9% dexamethasone (equivalent to 517 micrograms of dexamethasone).</description>
    <arm_group_label>DEXYCU (dexamethasone intraocular suspension) 9%.</arm_group_label>
    <other_name>dexamethasone intraocular suspension</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who underwent cataract surgery from 12Mar2019 to 15Dec2019 and received DEXYCU
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          -  Male and Female subjects at least 18 years of age

          -  Subjects who underwent cataract surgery from 12Mar2019 to 15Dec2019 and received
             DEXYCU

        Exclusion Criteria

        â€¢ Subjects who underwent cataract surgery and did not receive DEXYCU
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dario Paggiarino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Senior Vice President, Chief Medical Officer, EyePoint Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Keyur Patel, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>Vice President, Medical Affairs, EyePoint Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Flavio Leonin, Jr., MD</last_name>
    <role>Study Director</role>
    <affiliation>Senior Manager, Clinical Affairs, EyePoint Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Eye Center South Locations</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Eye Specialists</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard Eye Associates</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Vision Medical Group</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Eye Associates, Inc.</name>
      <address>
        <city>Rohnert Park</city>
        <state>California</state>
        <zip>94928</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Associates of Manatee, LLP</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Physicians of Pinellas, PA, dba The Eye Institute of West Florida</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacksoneye, SC</name>
      <address>
        <city>Lake Villa</city>
        <state>Illinois</state>
        <zip>60046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hauser-Ross Eye Institute</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Price Vision Group</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Physicians Eyecare Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Discover Vision Centers</name>
      <address>
        <city>Independence</city>
        <state>Missouri</state>
        <zip>64055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silverstein Eye Centers</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekwani Vision Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgery Center of Central New Jersey</name>
      <address>
        <city>Pennington</city>
        <state>New Jersey</state>
        <zip>08534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye Surgery Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10469</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SightMD, PLLC</name>
      <address>
        <city>Hauppauge</city>
        <state>New York</state>
        <zip>11788</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Eye Surgicenter</name>
      <address>
        <city>Westbury</city>
        <state>New York</state>
        <zip>11590</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Surgery Center</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VRF Eye Specialty Group</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute, PA</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Centers of Racine and Kenosha</name>
      <address>
        <city>Racine</city>
        <state>Wisconsin</state>
        <zip>53405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>May 1, 2020</last_update_submitted>
  <last_update_submitted_qc>May 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DEXYCU</keyword>
  <keyword>Cataract</keyword>
  <keyword>dexamethasone intraocular suspension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

